The EU variations framework has just been through its most significant revision in over a decade — and the rules changed on a different date from the guidance that explains them.
Commission Delegated Regulation (EU) 2024/1701 amended Regulation (EC) No 1234/2008 and has applied since 1 January 2025. But the European Commission’s revised Variations Guidelines only apply from 15 January 2026. For all of 2025, the new Regulation was in force while the older guidelines still governed classification — a gap that caught many holders out.
The timelines people get wrong
- Type IA: notified within 12 months of implementation, as an annual update. The 30 days often quoted is the authority’s reaction time, not your deadline.
- Minor variations requiring immediate notification: notified immediately after implementation — there is no fixed day count in the Regulation.
- Type IB: 30 days tacit approval, unchanged.
- Type II: 60 days by default, extendable to 90 for variations concerning a change to or addition of therapeutic indications. Importantly, the old fixed reduction to 30 days has been deleted — an authority may now shorten the period having regard to urgency, with no numeric floor.
New tools worth knowing
A new Article 7a introduces super-grouping: a single notification spanning more than one marketing authorisation held by the same holder — but only for Type IA variations, and only in cases listed in the Guidelines. A new Article 20(11) adds a voluntary worksharing route across several different holders in more than one Member State, while core worksharing remains mandatory.
The scope of extensions has narrowed to two headings: changes to the active substance, and changes to strength, pharmaceutical form or route. Influenza and coronavirus vaccine strain changes have been carved out and are no longer extensions.
Unforeseen changes and protocols
Article 5 now requires a classification recommendation for unforeseen variations within 60 days, with recommendations to be integrated into the guidelines over time. Post-approval change management protocols are anchored in the Regulation as a Type II variation — the protocol is agreed first, and the downgrade follows from it.
How PQRA helps
PQRA manages variations, groupings and worksharing across Greek and EU procedures — classifying correctly the first time and keeping your dossier current through its life.
No responses yet